Clinical Scorecard: Dr. Shannon Boye
At a Glance
| Category | Detail |
|---|---|
| Condition | Leber congenital amaurosis (LCA1) and X-linked retinoschisis (XLRS) |
| Key Mechanisms | Adeno-associated virus (AAV) technology for gene therapy |
| Target Population | Patients with LCA1 caused by biallelic mutations in GUCY2D and XLRS |
| Care Setting | Clinical trials and investigational studies |
Key Highlights
- Atsena Therapeutics is advancing ATSN-101 for LCA1 into pivotal trials.
- ATSN-201 has received RMAT status for XLRS, expediting its development.
- Novel AAV technologies enhance gene delivery and expand treatment options.
Guideline-Based Recommendations
Diagnosis
- Investigational studies to establish safety and efficacy of gene therapies.
Management
- Utilize AAV.SPR capsid for effective therapeutic gene delivery.
Monitoring & Follow-up
- Implement assays to measure long-term potency and patient reactions.
Risks
- Consider potential reactions to gene therapy products in patients.
Patient & Prescribing Data
Individuals with low vision or blindness due to genetic mutations.
Gene therapies are aimed at patients with no alternative treatment options.
Clinical Best Practices
- Show compelling evidence of efficacy in early trials to attract investment.
- Leverage dual AAV vector technology for large gene mutations.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.